310
Views
17
CrossRef citations to date
0
Altmetric
Original Articles

Increased myeloid-derived suppressor cells in patients with myelodysplastic syndromes suppress CD8+ T lymphocyte function through the STAT3-ARG1 pathway

, , , , , , , , & show all
Pages 218-223 | Received 07 Jan 2020, Accepted 22 Aug 2020, Published online: 26 Sep 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Fang Shao, Jie Pan, Yewen Xie, Jun Ding, Xiao Sun, Lei Xia, Dawei Zhu, Shizhong Wang & Chunjian Qi. Sulforaphane Attenuates AOM/DSS-Induced Colorectal Tumorigenesis in Mice via Inhibition of Intestinal Inflammation. Nutrition and Cancer 0:0, pages 1-12.
Read now

Articles from other publishers (16)

Caroline M. Putnam, Lahari Kondeti, Meredith B. A. Kesler & Melinda E. Varney. (2023) Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia. Biochemistry and Cell Biology 101:6, pages 481-495.
Crossref
Vaishali Bhardwaj & Stephen M. Ansell. (2023) Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies. Frontiers in Cell and Developmental Biology 11.
Crossref
Shifen Wang, Xingyun Zhao, Siwen Wu, Dawei Cui & Zhenshu Xu. (2023) Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomarker Research 11:1.
Crossref
晓华 张. (2023) The Role and Research Progress of NLRP3 Inflammasome and MDSC in Myelodysplastic Syndrome. Advances in Clinical Medicine 13:03, pages 3932-3936.
Crossref
Xiaoying Zhang, Xingcheng Yang, Ling Ma, Yicheng Zhang & Jia Wei. (2023) Immune dysregulation and potential targeted therapy in myelodysplastic syndrome. Therapeutic Advances in Hematology 14.
Crossref
Likun Zheng, Lei Zhang, Yixuan Guo, Xintong Xu, Zhaoyun Liu, Zhenyu Yan & Rong Fu. (2022) The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome. Frontiers in Immunology 13.
Crossref
Shunjie Yu, Xiaotong Ren & Lijuan Li. (2022) Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin. Experimental Hematology & Oncology 11:1.
Crossref
Olga Kouroukli, Argiris Symeonidis, Periklis Foukas, Myrto-Kalliopi Maragkou & Eleni P. Kourea. (2022) Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. Cancers 14:22, pages 5656.
Crossref
Maria Velegraki, Andrew Stiff, Helen A. Papadaki & Zihai Li. (2022) Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS. Journal of Clinical Medicine 11:16, pages 4908.
Crossref
Yannick Simoni & Nicolas Chapuis. (2022) Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications. Diagnostics 12:7, pages 1659.
Crossref
Chiara Cioccarelli & Barbara Molon. (2022) MDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech. Clinical and Experimental Immunology 208:2, pages 147-157.
Crossref
Huijuan Jiang, Xiaoyu Zhao, Mengtong Zang, Rong Fu, Zonghong Shao & Chunyan Liu. (2022) Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome. Oxidative Medicine and Cellular Longevity 2022, pages 1-21.
Crossref
Olivia Lynch & Laura Calvi. (2022) Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review. Cells 11:3, pages 580.
Crossref
Yingying Sun, Xiaoqing Han, Chao Shang, Yawei Wang, Boya Xu, Shu Jiang, Yan Mo, Dake Wang, Yueshuang Ke & Xianlu Zeng. (2022) The downregulation of type I IFN signaling in G-MDSCs under tumor conditions promotes their development towards an immunosuppressive phenotype. Cell Death & Disease 13:1.
Crossref
Angèle Luby & Marie-Clotilde Alves-Guerra. (2021) Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy. Cancers 13:23, pages 5912.
Crossref
Suncica Kapor & Juan F. Santibanez. (2021) Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies. Journal of Clinical Medicine 10:13, pages 2788.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.